This article was originally published Oct. 27.
By Julia Karow
Illumina said last week that demand for the HiSeq 2000 continued to exceed its expectations during the third quarter, prompting it to further increase production of the instrument.
HiSeq Sales Boost Illumina's Q3 Revenues, but Order Backlog Will Take Several Quarters to Fill
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.